Exact Mass: 735.2105

Exact Mass Matches: 735.2105

Found 15 metabolites which its exact mass value is equals to given mass value 735.2105, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Anthemis glycoside B

Anthemis glycoside B

C34H41NO17 (735.2374)


An anthemis glycoside that is found in the cyanogenic achenes of Anthemis altissima.

   

Chiapenine ES-IV

Chiapenine ES-IV

C34H41NO17 (735.2374)


   

(8S)-O3-{3-amino-N-[(S)-3-((R)-2-amino-2-carboxy-ethylsulfanyl)-1-carboxy-propyl]-beta-D-xylo-3,4-dideoxy-hexopyranuronamidosyl}-8-(2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-4-ureido-L-erythro-L-gluco-2,6;5,8-dianhydro-4-deoxy-octonic acid|Ezomycin B1|ezomycin-B1

(8S)-O3-{3-amino-N-[(S)-3-((R)-2-amino-2-carboxy-ethylsulfanyl)-1-carboxy-propyl]-beta-D-xylo-3,4-dideoxy-hexopyranuronamidosyl}-8-(2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-4-ureido-L-erythro-L-gluco-2,6;5,8-dianhydro-4-deoxy-octonic acid|Ezomycin B1|ezomycin-B1

C26H37N7O16S (735.2017)


   
   
   

Rilapladib

Rilapladib

C40H38F5N3O3S (735.2554)


C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent Rilapladib (SB 659032) is a selective Lp-PLA2 (lipoprotein-associated phospholipase A2) inhibitor with an IC50 of 230 pM[1]. Rilapladib (SB 659032) is also a PAFR (Platelet Activating Factor Receptor) antagonist[2].

   

[(2R,3R,4R,5S,6R)-3-amino-2-[[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl] (3R)-3-hydroxydecanoate

[(2R,3R,4R,5S,6R)-3-amino-2-[[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl] (3R)-3-hydroxydecanoate

C25H43N3O18P2 (735.2017)


   

N-[(3R,9S,10S)-9-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methoxybenzenesulfonamide

N-[(3R,9S,10S)-9-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methoxybenzenesulfonamide

C36H47Cl2N3O7S (735.2512)


   

(2S,3R,4S,5R,6R)-6-[(2R,3S,4R,5R,6R)-6-[[(2R,3S,4R,5R,6R)-5-acetamido-4-hydroxy-6-methoxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid

(2S,3R,4S,5R,6R)-6-[(2R,3S,4R,5R,6R)-6-[[(2R,3S,4R,5R,6R)-5-acetamido-4-hydroxy-6-methoxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid

C27H45NO22 (735.2433)


   

[20,22,25-tris(acetyloxy)-15,19,26-trihydroxy-3,15,26-trimethyl-6,16,23-trioxo-2,5,17-trioxa-11-azapentacyclo[16.7.1.0¹,²¹.0³,²⁴.0⁷,¹²]hexacosa-7,9,11-trien-21-yl]methyl acetate

[20,22,25-tris(acetyloxy)-15,19,26-trihydroxy-3,15,26-trimethyl-6,16,23-trioxo-2,5,17-trioxa-11-azapentacyclo[16.7.1.0¹,²¹.0³,²⁴.0⁷,¹²]hexacosa-7,9,11-trien-21-yl]methyl acetate

C34H41NO17 (735.2374)


   

[(e)-[2-(4-hydroxyphenyl)-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl}ethylidene]amino]oxysulfonic acid; sinapoylcholine

[(e)-[2-(4-hydroxyphenyl)-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl}ethylidene]amino]oxysulfonic acid; sinapoylcholine

[C30H43N2O15S2]+ (735.2105)


   

12-(acetyloxy)-6-[(acetyloxy)methyl]-7-(benzoyloxy)-5-(furan-3-carbonyloxy)-2-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-8-yl 1-methyl-6-oxopyridine-3-carboxylate

12-(acetyloxy)-6-[(acetyloxy)methyl]-7-(benzoyloxy)-5-(furan-3-carbonyloxy)-2-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-8-yl 1-methyl-6-oxopyridine-3-carboxylate

C38H41NO14 (735.2527)


   

[(1r,3r,15s,18r,19r,20s,21r,22r,24s,25r,26r)-20,22,25-tris(acetyloxy)-15,19,26-trihydroxy-3,15,26-trimethyl-6,16,23-trioxo-2,5,17-trioxa-11-azapentacyclo[16.7.1.0¹,²¹.0³,²⁴.0⁷,¹²]hexacosa-7,9,11-trien-21-yl]methyl acetate

[(1r,3r,15s,18r,19r,20s,21r,22r,24s,25r,26r)-20,22,25-tris(acetyloxy)-15,19,26-trihydroxy-3,15,26-trimethyl-6,16,23-trioxo-2,5,17-trioxa-11-azapentacyclo[16.7.1.0¹,²¹.0³,²⁴.0⁷,¹²]hexacosa-7,9,11-trien-21-yl]methyl acetate

C34H41NO17 (735.2374)


   

[(1s,3r,15s,18s,19r,20r,21s,22s,24r,25r,26s)-20,22,25-tris(acetyloxy)-15,19,26-trihydroxy-3,15,26-trimethyl-6,16,23-trioxo-2,5,17-trioxa-11-azapentacyclo[16.7.1.0¹,²¹.0³,²⁴.0⁷,¹²]hexacosa-7,9,11-trien-21-yl]methyl acetate

[(1s,3r,15s,18s,19r,20r,21s,22s,24r,25r,26s)-20,22,25-tris(acetyloxy)-15,19,26-trihydroxy-3,15,26-trimethyl-6,16,23-trioxo-2,5,17-trioxa-11-azapentacyclo[16.7.1.0¹,²¹.0³,²⁴.0⁷,¹²]hexacosa-7,9,11-trien-21-yl]methyl acetate

C34H41NO17 (735.2374)


   

(1r,2r,5r,6r,7r,8r,9s,12s)-12-(acetyloxy)-6-[(acetyloxy)methyl]-7-(benzoyloxy)-5-(furan-3-carbonyloxy)-2-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-8-yl 1-methyl-6-oxopyridine-3-carboxylate

(1r,2r,5r,6r,7r,8r,9s,12s)-12-(acetyloxy)-6-[(acetyloxy)methyl]-7-(benzoyloxy)-5-(furan-3-carbonyloxy)-2-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-8-yl 1-methyl-6-oxopyridine-3-carboxylate

C38H41NO14 (735.2527)